Vitoc Vlad 4

What Happened

• Vitoc Vlad, CEO of MAIA Biotechnology, was granted a derivative award on April 10, 2026: options covering 800,000 shares of MAIA common stock. The Form 4 reports the acquisition price as $0.00 (grant); the filing does not state an exercise price or immediate cash value. This is an equity award (not a sale or open-market purchase).

Key Details

• Transaction date: 2026-04-10; Form 4 filed: 2026-04-14 (timely filing).
• Transaction type/code: A (award/grant of a derivative security — stock options).
• Shares/options granted: 800,000 options; reported acquisition price: $0.00.
• Shares owned after transaction: Not reported in the provided data.
• Footnote: Options vest over a four-year schedule — 25% vest on the first anniversary of the grant, then the remainder vests ratably monthly over the following 36 months.
• No indication in this filing of an immediate exercise, sale, tax-withholding, or a 10b5-1 plan.

Context

• These are stock options (a derivative grant). Vesting means the award is not immediately exercisable in full; the CEO will earn exercisable portions over four years per the stated schedule. Equity grants are a common form of executive compensation intended to align management with long-term shareholder value; they do not by themselves represent a cash purchase or sale.